Somatic activating mutations in the RAS‐MAPK pathway genes KRAS, EGFR, and BRAF were, respectively, identified in 30%, 14%, and 4% of lung adenocarcinoma with mutual exclusion in Caucasian population.5 Targeted therapies have been developed alone or in combination, allowing an increased in survival in patients with metastatic lung adenocarcinomas, especially in case of EGFR mutations. The gene discussed is KRAS; the disease is lung adenocarcinoma.